Literature DB >> 3664241

Outcome of surgery for Graves' disease re-examined.

E L Cusick1, Z H Krukowski, N A Matheson.   

Abstract

The outcome of surgery for Graves' disease in terms of early and late morbidity was studied in 161 patients undergoing subtotal thyroidectomy in the 10-year period 1976-1985. Eighty of these patients had a minimum follow-up of 5 years. There was a low operative morbidity and a zero mortality. The weight of thyroid tissue preserved (in the range 5-10 g) influenced the prevalence of hypothyroidism at one year and at five years. There was a cumulative incidence of hypothyroidism which could not be reliably predicted from biochemical results during the first year. Over 60 per cent of patients with subclinical hypothyroidism at 4 months (63 per cent) or 1 year (70 per cent) did not subsequently need thyroxine replacement within 5 years. Patients remained at risk of developing recurrent toxicity indefinitely and the risk was significantly greater in patients with small goitres (less than 50 g). Our results may be improved by leaving larger remnants (9-10 g) in most patients and smaller remnants (2-4 g) in those with small glands in whom alternative treatment, which is to be preferred, is not acceptable. After subtotal thyroidectomy for Graves' disease lifelong follow-up is necessary.

Entities:  

Mesh:

Year:  1987        PMID: 3664241     DOI: 10.1002/bjs.1800740909

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  11 in total

Review 1.  Thyroid swelling--a protocol for management.

Authors:  W E Thomas
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

Review 2.  The role of surgery in primary hyperthyroidism.

Authors:  A P Weetman
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

Review 3.  Consensus statement for good practice and audit measures in the management of hypothyroidism and hyperthyroidism. The Research Unit of the Royal College of Physicians of London, the Endocrinology and Diabetes Committee of the Royal College of Physicians of London, and the Society for Endocrinology.

Authors:  M P Vanderpump; J A Ahlquist; J A Franklyn; R N Clayton
Journal:  BMJ       Date:  1996-08-31

4.  Subtotal thyroidectomy: a reliable method to achieve euthyroidism in Graves' disease. Prognostic factors.

Authors:  Pablo Moreno; José M Gómez; Núria Gómez; José M Francos; Emilio Ramos; Antonio Rafecas; E Jaurrieta
Journal:  World J Surg       Date:  2006-11       Impact factor: 3.352

5.  Iodine therapy for thyroidectomy patients exhibiting high thyroid-stimulating hormone values: a randomised study.

Authors:  J D Taylor; S N Radcliffe; P K Basu; P Atkins
Journal:  Ann R Coll Surg Engl       Date:  1993-05       Impact factor: 1.891

6.  Follow-up evaluation of patients with Graves' disease treated by subtotal thyroidectomy and risk factor analysis for post-operative thyroid dysfunction.

Authors:  K Sugino; T Mimura; K Toshima; H Iwabuchi; Y Kitamura; M Kawano; O Ozaki; K Ito
Journal:  J Endocrinol Invest       Date:  1993-03       Impact factor: 4.256

7.  Complications of thyroid surgery.

Authors:  D B de Roy van Zuidewijn; I Songun; J Kievit; C J van de Velde
Journal:  Ann Surg Oncol       Date:  1995-01       Impact factor: 5.344

8.  Early recurrence of hyperthyroidism in patients with Graves' disease treated by subtotal thyroidectomy.

Authors:  K Sugino; T Mimura; O Ozaki; Y Kure; H Iwasaki; N Wada; A Matsumoto; K Ito
Journal:  World J Surg       Date:  1995 Jul-Aug       Impact factor: 3.352

9.  Retrospective analysis of prognostic factors affecting the thyroid functional status after subtotal thyroidectomy for Graves' disease.

Authors:  T Okamoto; Y Fujimoto; T Obara; Y Ito; M Aiba
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

10.  Could total thyroidectomy become the standard treatment for Graves' disease?

Authors:  Ayhan Koyuncu; Cengiz Aydin; Omer Topçu; Oruç Numan Gökçe; Sahande Elagöz; Hatice Sebila Dökmetaş
Journal:  Surg Today       Date:  2009-12-29       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.